We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
+27.7%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$235M
AUM Growth
-$117M
Cap. Flow
-$152M
Cap. Flow %
-64.44%
Top 10 Hldgs %
95.58%
Holding
18
New
1
Increased
–
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
CCXI
ChemoCentryx, Inc.
CCXI
+$857K

Top Sells

Rank Stock Value
1
RNA
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
+$117M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$20M
3
CEMP
Cempra, Inc.
CEMP
+$5.71M
4
SUPN icon
Supernus Pharmaceuticals
SUPN
+$5.44M
5
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$4.71M

Sector Composition

Rank Sector Weight
1 Healthcare 77.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SIEN
1
DELISTED
Sientra, Inc.
SIEN
$42M 17.88%
219,901
– –
PRTK
2
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$40.1M 17.03%
1,301,413
– –
SUPN icon
3
Supernus Pharmaceuticals
SUPN
$2.59B
$27.8M 11.83%
2,303,462
-575,866
-20% -$5.44M
DRNA
4
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$23.4M 9.93%
972,734
-209,462
-18% -$4.71M
TARA icon
5
Protara Therapeutics
TARA
$220M
$22.7M 9.64%
50,447
– –
AMRN
6
Amarin Corp
AMRN
$299M
$18.9M 8.05%
404,374
– –
CEMP
7
DELISTED
Cempra, Inc.
CEMP
$18M 7.65%
524,285
-190,000
-27% -$5.71M
EVAR
8
DELISTED
Lombard Medical, Inc.
EVAR
$13.2M 5.61%
3,473,452
– –
PTLA
9
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$13.2M 5.61%
347,349
-583,333
-63% -$20M
RGLS
10
DELISTED
Regulus Therapeutics
RGLS
$5.54M 2.36%
2,728
– –
ZGNX
11
DELISTED
Zogenix, Inc.
ZGNX
$3.2M 1.36%
291,902
– –
HPTX
12
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$2.87M 1.22%
62,500
– –
ANTH
13
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$1.96M 0.83%
54,749
– –
ACHV icon
14
Achieve Life Sciences
ACHV
$659M
$1.27M 0.54%
274
– –
CCXI
15
DELISTED
ChemoCentryx, Inc.
CCXI
$824K 0.35%
+109,700
New +$857K
DCOY
16
Decoy Therapeutics
DCOY
$2.19M
– –
0
– –
ZLCS
17
DELISTED
ZALICUS INC COM NEW
ZLCS
$70K 0.03%
7,896
– –
RNA
18
DELISTED
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
– –
-6,213,924
Closed -$117M

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q1 2015 Portfolio in Review

As of Q1 2015, Abingworth held 18 positions worth $235M, down 33% from $352M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Abingworth withdrew a net $152M in Q1 2015, closing 1 position and reducing 4 holdings. Its most notable exit was PROSENSA HLDGS N V ORD SHS (NLD), an estimated $117M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 47% a quarter earlier.

Against the trend, Abingworth opened a new position in ChemoCentryx, Inc. worth $824K.

  • Abingworth's largest Q1 2015 buy was ChemoCentryx, Inc.: 109,700 shares worth $824K.
  • Abingworth's biggest Q1 2015 reduction was Portola Pharmaceuticals, Inc., cutting an estimated $20M.
  • Abingworth fully exited PROSENSA HLDGS N V ORD SHS (NLD) in Q1 2015, selling an estimated $117M.
  • Abingworth's ten largest holdings make up 96% of its $235M portfolio in Q1 2015.
  • Abingworth opened 1 new position and closed 1 in Q1 2015.
  • Abingworth's portfolio value fell 33% quarter-over-quarter to $235M.

Based on Abingworth's 13F filing for Q1 2015, filed 14 May 2015.